Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in Germany

5 March 2019 - The decision matrix applied by the IQWiG for the quantification of added benefit within the early benefit ...

Read more →

Germany agrees on new pharmaceutical bill

13 February 2019 - On 30 January, the German government has agreed on a draft Act for more safety in ...

Read more →

Erenumab in migraine: indication of a significant added benefit for certain patients

2 February 2019 - As a prophylaxis successful when other drug therapies are exhausted. ...

Read more →

Citizens ask - scientists answer: the IQWiG sets four new topics for HTA reports

23 January 2019 - Citizens, patients and medical experts: selection of topics with a sense of proportion ...

Read more →

Progressive squamous cell carcinoma of the head and neck: pembrolizumab prolongs survival

15 January 2019 - Only a few study participants were treated in compliance with the approval, therefore the extent of ...

Read more →

2018 in a nutshell: new edition with facts and graphics from the IQWiG

9 January 2019 - The focus of the 33-page brochure is information, overviews and charts on "Health Technology Assessment (HTA) ...

Read more →

AMNOG as a learning system: new study on ingenol mebutate in actinic keratosis shows added benefit

3 December 2018 - Advantage over diclofenac in complete clearance of visible lesions / unclear sustainability of treatment effect ...

Read more →

Underuse of innovative medicines in Germany: A justification for government intervention?

6 December 2018 - The German market for innovative medicines is characterised by simultaneous underuse and overuse.  ...

Read more →

German health minister calls for faster adoption of biosimilar drugs

14 November 2018 - Germany’s health minister Jens Spahn has called for faster adoption of cheaper copies of biotech drugs ...

Read more →

Pertuzumab in early breast cancer: no proof of an additional benefit despite exemplary surrogate validation

1 October 2018 - Effect on disease-free survival too small to conclude on overall survival. ...

Read more →

A breakthrough cancer drug has been approved. Now comes the battle over the price.

12 Septemner 2018 - Novartis' breakthrough cancer drug Kymriah has been approved in Europe. Now comes the debate about its ...

Read more →

Haemophilia A and sialorrhoea: contemporary comparative therapies not implemented so added benefit not proven

2 July 2018 - Of the four dossier evaluations published by the IQWiG on 2 July, two have a striking similarity ...

Read more →

Confirmatory versus explorative endpoint analysis: decision-making on the basis of evidence available from market authorisation and early benefit assessment for oncology drugs

21 June 2018 - The early benefit assessment of pharmaceuticals in Germany and their preceding market authorisation pursue different objectives. ...

Read more →

Effect of cross-over in oncology clinical trials on evidence levels in early benefit assessment in Germany

13 June 2018 - In oncology clinical trials, cross-over is used frequently but may lead to uncertainties regarding treatment effects. ...

Read more →

Metastatic breast cancer: highly selective post-hoc analysis rather than complete publication of quality of life data

13 June 2018 - IQWiG employees criticise the publication practice of PALOMA-2 study authors. ...

Read more →